KDR and neoplasm: By therapeutic targeting of VEGFA or its main receptor, VEGF receptor-2 (VEGFR2), the barrier can be stabilized, resulting in reduced interstitial pressure, increased perfusion of tumor vessels, decreased malignant invasion and metastatic spread, enhanced infiltration and activation of immune cells, and improved therapy response (5, 6).